BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 2567208)

  • 21. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
    Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
    Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells.
    Kharbanda SM; Sherman ML; Kufe DW
    Blood; 1990 Feb; 75(3):583-8. PubMed ID: 1967538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
    Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
    Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tiazofurin decreases Ras-GTP complex in K562 cells.
    Hata Y; Natsumeda Y; Weber G
    Oncol Res; 1993; 5(4-5):161-4. PubMed ID: 8305741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells.
    Olah E; Kote Z; Natsumeda Y; Yamaji Y; Jarai G; Lapis E; Financsek I; Weber G
    Cancer Biochem Biophys; 1990 Apr; 11(2):107-17. PubMed ID: 1974479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase.
    Yu J; Lemas V; Page T; Connor JD; Yu AL
    Cancer Res; 1989 Oct; 49(20):5555-60. PubMed ID: 2571408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
    Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
    Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of de novo and salvage pathways in chemotherapy.
    Weber G; Nagai M; Natsumeda Y; Ichikawa S; Nakamura H; Eble JN; Jayaram HN; Zhen WN; Paulik E; Hoffman R
    Adv Enzyme Regul; 1991; 31():45-67. PubMed ID: 1877399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
    Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
    Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells.
    Natsumeda Y; Ikegami T; Olah E; Weber G
    Cancer Res; 1989 Jan; 49(1):88-92. PubMed ID: 2461800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purine metabolism of human glioblastoma in vivo.
    Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
    Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line.
    Lucas DL; Webster HK; Wright DG
    J Clin Invest; 1983 Dec; 72(6):1889-900. PubMed ID: 6139386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
    Roberts JD; Stewart JA; McCormack JJ; Krakoff IR; Culham CA; Hartshorn JN; Newman RA; Haugh LD; Young JA
    Cancer Treat Rep; 1987 Feb; 71(2):141-9. PubMed ID: 3802111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IMP dehydrogenase and action of antimetabolites in human cultured blast cells.
    Yamada Y; Goto H; Yoshino M; Ogasawara N
    Biochim Biophys Acta; 1990 Mar; 1051(3):209-14. PubMed ID: 1968764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.
    Pillwein K; Jayaram HN; Weber G
    Blut; 1988 Aug; 57(2):97-100. PubMed ID: 3165681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.